Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAID: Intensive BP Control in Acute Type B Aortic Dissection
NCT03001739Phase 1Unknown
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Dec 2016
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of urapidil in Acute Type B Aortic Dissection (2 arms), sponsored by Sir Run-Run Shaw Hospital. Primary endpoint: Composite in-hospital adverse outcome up to 3 months. Status: unknown.
02
Drugs
urapidil
03
Conditions
Acute Type B Aortic Dissection
Beyond the preview
Go deeper on NCT03001739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03001739.